Search Articles — Sudonull

Search Results

In this project

Meta is developing a wearable AI device: Zuckerberg's strategy

https://sudonull.com/meta-is-developing-a-wearable-ai-device-zuckerberg-s-strategy

Meta has confirmed the development of a wearable AI device. We analyze the 'octopus' strategy, Hatch subscription, competition with Apple, and privacy risks. Read the details.

Well Logging Probe on STM32F401 for Wells

https://sudonull.com/well-logging-probe-on-stm32f401-for-wells

Development of a universal probe for GK, KS, RM in water wells. STM32F401, SiPM, depth synchronization. Technical details for developers. Study the schematic and results.

From other projects

How to Negotiate a Raise at Work: Data-Driven Guide

https://ymaho.com/how-to-negotiate-a-raise-at-work-data-driven-guide

82% of those who ask get a raise. Learn evidence-based tactics, scripts, and timing strategies to negotiate your salary successfully. Start today.

FDA will approve subcutaneous Lecanemab in August 2026

https://ymaho.com/fda-will-approve-subcutaneous-lecanemab-in-august-2026

Analysis of the FDA decision postponement for Leqembi IQLIK to August 24: why this is a signal for approval, not a delay. Benefits for Alzheimer's patients and market forecast. Read key takeaways.

Meerdink Teams Up with Makaay for Oranje Return

https://lrivo.com/meerdink-teams-up-with-makaay-for-oranje-return

Mexx Meerdink enlists Roy Makaay to sharpen his finishing and push for a Dutch national team recall ahead of Euro qualifiers. Learn how this mentorship could change his career.

Smart drugs for cancer and HIV: development by Siberian scientists

https://ymaho.com/smart-drugs-for-cancer-and-hiv-development-by-siberian-scientists

Institute of the Siberian Branch of the Russian Academy of Sciences creates therapeutic oligonucleotides — molecules that switch off cancer and HIV genes. The development of phosphorylguanidines promises treatment without side effects. Learn how Russian genetic engineering bypasses Western patents.

Gene therapy OPGx-LCA5 accepted into FDA RDEP program

https://ymaho.com/gene-therapy-opgx-lca5-accepted-into-fda-rdep-program

Learn how Opus Genetics' gene therapy OPGx-LCA5 received RDEP status from the FDA, accelerating the development of treatment for ultra-rare LCA5 blindness in children. Detailed analysis and prospects.

Trending Now